Correction: Closing in on a new treatment for sleeping sickness

Closing in on a new treatment for sleeping sickness

A chemoproteomics approach has been employed to identify a kinase that could be used as a druggable target in efforts to develop new treatments for African sleeping sickness.

some new leads for human african trypanosomiasis (african sleeping sickness)

Treatment of Rhodesian sleeping sickness in Kenya.

In a study of 269 sleeping sickness patients treated with Mel-B, 14 (5.2%) died during treatment. With total dosages of at least 30 ml (1.08 g), 1.4% relapsed and another 6.4% died, mostly of unknown causes, within three years of treatment, giving a success rate of 92.1% over the three years. Mel-B was used to treat 55 relapses after suramin therapy with 1.8% deaths during treatment, 3.6% relap...

Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping Sickness

BACKGROUND Human African trypanosomiasis (HAT), also known as sleeping sickness, is a fatal parasitic disease caused by trypanosomes. Current treatment options for HAT are scarce, toxic, no longer effective, or very difficult to administer, in particular for the advanced, fatal stage of the disease (stage 2, chronic HAT). New safe, effective and easy-to-use treatments are urgently needed. Here ...

Sleeping Sickness Wakes Again

Sleeping sickness of horses was, as reeentiy as the IQSO's, the most devastating livestock disease in the United States. Horses died by the hundreds of thousands in the Midwestern United States, in California, and along the Atlantic seaboard at a period which coincided with the beginning of the sharp decline in the use of horses on the farm. Losses were so severe in some areas that the inevitab...